Product image of Linezolid Hikma (Linezolid) supplied by GNH India

Linezolid Hikma

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Hikma (Linezolid)

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone presented as an intravenous solution for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, as well as infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH India supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is an oxazolidinone antibiotic used to treat serious bacterial infections.

  • Complicated skin and soft tissue infections: provides clinical cure against Gram‑positive pathogens, including MRSA.
  • Community‑acquired and nosocomial pneumonia: eradicates causative bacteria and improves respiratory outcomes.
  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers bacteriostatic activity against MRSA strains.
  • Vancomycin‑resistant Enterococcus (VRE) infections: serves as an alternative therapeutic option for VRE infections.

How It Works

  • Linezolid binds to the 50S ribosomal subunit of susceptible bacteria, preventing the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth by blocking translation, resulting in a bacteriostatic effect against Gram‑positive organisms, including resistant strains such as MRSA and VRE.

Side Effects

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, usually self‑limiting.
  • Headache: transient cranial discomfort.
  • Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects

  • Myelosuppression: significant decrease in blood cell lines, requiring monitoring.
  • Peripheral neuropathy: nerve damage presenting as tingling or numbness.
  • Lactic acidosis: rare metabolic disturbance with high mortality.
  • Serotonin syndrome: risk when combined with serotonergic agents.

Precautions & Warnings

When using Linezolid, several safety considerations should be observed.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic dysfunction: use with caution; periodic liver‑function tests are recommended.
  • Hematologic monitoring: perform regular complete blood counts due to risk of thrombocytopenia.
  • Concomitant serotonergic drugs: avoid or closely monitor for serotonin syndrome.
  • Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk.
  • Store at ambient temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Linezolid interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

  • Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome.
  • Monoamine oxidase inhibitors (MAOIs): increased serotonin toxicity.
  • Rifampin: may reduce linezolid plasma concentrations.
  • Erythromycin: may increase linezolid levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

  • Warfarin: possible alteration of INR; monitor coagulation parameters.
  • Anticonvulsants (e.g., carbamazepine): may affect metabolism; observe therapeutic response.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive risk of thrombocytopenia.

Frequently Asked Questions

Linezolid Hikma is an intravenous oxazolidinone antibiotic indicated for the treatment of complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, as well as infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE) in adult patients.

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This prevents the formation of the initiation complex required for translation, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE.

The specific dosing regimen for Linezolid Hikma is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals should follow local guidelines and product labeling.

Safety data for Linezolid during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Linezolid Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Linezolid is often compared with vancomycin, another agent for Gram‑positive infections. While vancomycin is bactericidal, linezolid is bacteriostatic and offers oral bioavailability, which vancomycin lacks. Linezolid also retains activity against some vancomycin‑resistant strains, but both require monitoring for hematologic toxicity.

Linezolid Hikma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light and moisture, and keep it out of reach of children. Do not freeze the product.

Linezolid Hikma is administered intravenously by slow infusion, typically over 30 to 60 minutes, as directed by the prescriber. The infusion should be prepared using aseptic technique and administered using appropriate IV equipment.

Serious adverse events include myelosuppression (especially thrombocytopenia and anemia), peripheral neuropathy, lactic acidosis, and serotonin syndrome when combined with serotonergic agents. Patients should be monitored regularly for blood‑cell counts, neurological symptoms, and metabolic disturbances.

Linezolid Hikma is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in individuals currently receiving monoamine oxidase inhibitors (MAOIs) and used with caution in patients on serotonergic medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.